

NIHB – Rheumatology Cheat Sheet (last updated 2018.05.07)

*Summary of Limited Use Updates for 2018:

Granulomatosis with Polyangiitis and Microscopic Polyangiitis: The criteria for induction of remission with Rituximab is set as a dose of 375 mg/m² body surface area, weekly x 4 weeks, for patients with severely active disease AND who have failed an adequate trial of cyclophosphamide OR who have a contraindication to cyclophosphamide.

Biosimilars:

- Infliximab: Inflectra is listed on the NIHB formulary since May 2017, and is provided for all new requests for infliximab in RA, PsA and AS. To encourage uptake of Inflectra, approvals will be valid indefinitely, with no renewal forms required.
- Etanercept: Brenzys was added to the formulary in September 2017, and Erelzi was added in February 2018. Either will be provided for all new requests for infliximab in RA, polyarticular JIA and AS. To encourage uptake, approvals will be valid indefinitely, with no renewal forms required.

Juvenile Idiopathic Arthritis:

- The dosing of adalimumab and etanercept has been updated.
- Response criteria are standardized across all agents as a 30% improvement in 3 of 6 clinical parameters (any 3 of number of active joints, number of joints with loss of range of motion, physician global assessment scale, patient or parent global assessment scale, CHAQ, ESR) AND that no more than one of these variables has worsened by >30%.

Rheumatoid Arthritis:

- Response criteria are standardized across all agents as a 20% improvement in 3 of 5 clinical parameters (tender and swollen joint counts, AND physician global, AND either patient global OR ESR/CRP).

Psoriatic Arthritis:

- NSAID requirement: The definition of refractory disease across all agents is now a trial of 2 different agents at maximum tolerated doses for a combined duration of 4 weeks.
- DMARD requirement: The definition of refractory disease has been changed to a requirement of ANY 2 of methotrexate, leflunomide, sulfasalazine or cyclosporine (i.e. the formulary no longer mandates a methotrexate trial, and gold has been deleted from the list of suggested DMARDs).
- Inflectra has been added to the formulary for this disease indication.
- Response criteria are standardized across all biologics to be based on the PsARC criteria (Improvement in at least two of the four PsARC criteria, one of which has to be joint tenderness or swelling score, with no worsening in any of the four criteria. A response in joint count is determined by a reduction of ≥ 30%. A response in the Physician or Patient Global Assessment scale is determined by a reduction of 1 point).
- Cosentyk (secukinumab) is now covered by NIHB effective April 12, 2018.

Ankylosing Spondylitis:

- NSAID requirement: The definition of refractory disease across all agents is now a trial of 2 different agents at maximum tolerated doses for a combined duration of 4 weeks.
- DMARD requirement for peripheral joint disease: The definition is now a trial of 8 weeks of methotrexate and 3 months of sulfasalazine.
- Inflectra has been added to the formulary for this disease indication.
- Response criteria are standardized across all biologics to be based on a BASDAI response (Improvement of at least 50% or 2 units)
- Cosentyk (secukinumab) is now covered by NIHB effective April 12, 2018.

Pain Management:

- Celebrex is an open access benefit. No prior approval is required.
- Opioids: the maximum morphine equivalents per day for non-cancer, non-palliative pain was decreased to a total of 400 mg morphine equivalents per day. This limit will be calculated based on the total dose of all opioids a client is receiving from NIHB within a 30-day period (i.e. 12000 morphine equivalents over 30 days). The Program will continue to evaluate this dose limit based on current Canadian opioid guidelines.

Important Links:

Click here for the Winter 2018 NIHB formulary: [NIHB Winter 2018](#)

Biologics for Inflammatory Arthritis Conditions

ANKYLOSING SPONDYLITIS

<u>Biologic/Biosimilar</u>	<u>Etanercept (Enbrel)</u>	<u>Etanercept (Brenzys)</u>	<u>Certolizumab Pegol</u>	<u>Adalimumab</u>	<u>Golimumab</u>	<u>Infliximab (Remicade)</u>	<u>Inflectra</u>	<u>Secukinumab</u>
Maximum Dose	50 mg weekly	50 mg weekly	400mg at weeks 0, 2, and 4, followed by 200mg every other week or 400mg every 4 weeks	40 mg q2weeks	50 mg monthly	Not on formulary for this indication	5 mg/kg at weeks 0, 2 and 6	150 mg Weeks 0, 1, 2, 3, 4 and then 150 mg monthly
Initial Criteria (1 year and prescribed by a rheumatologist)	BASDAI > 4 AND  Refractory to a trial of 2 different NSAIDs at maximum tolerated doses for a combined total duration of at least 4 weeks	BASDAI > 4 AND  Refractory to a trial of 2 different NSAIDs at maximum tolerated doses for a combined total duration of at least 4 weeks	BASDAI > 4  AND  Refractory to a trial of 2 different NSAIDs at maximum tolerated doses for a combined total duration of at least 4 weeks	BASDAI > 4 AND  Refractory to a trial of 2 different NSAIDs at maximum tolerated doses for a combined total duration of at least 4 weeks	BASDAI > 4 AND  Refractory to a trial of 2 different NSAIDs at maximum tolerated doses for a combined total duration of at least 4 weeks	Not on formulary for this indication	BASDAI > 4 AND  Refractory to a trial of 2 different NSAIDs at maximum tolerated doses for a combined total duration of at least 4 weeks	BASDAI > 4 AND Refractory to a trial of 2 different NSAIDs at maximum tolerated doses for a combined total duration of at least 4 weeks
<u>Additional Initial Criteria for PERIPHERAL JOINT DISEASE</u>	Refractory to weekly parenteral or oral methotrexate at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks AND Sulfasalazine 2g/day for at least 3 months	Refractory to weekly parenteral or oral methotrexate at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks AND Sulfasalazine 2g/day for at least 3 months	Refractory to weekly parenteral or oral methotrexate at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks AND Sulfasalazine 2g/day for at least 3 months	Refractory to weekly parenteral or oral methotrexate at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks AND Sulfasalazine 2g/day for at least 3 months	Refractory to weekly parenteral or oral methotrexate at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks AND Sulfasalazine 2g/day for at least 3 months	Not on formulary for this indication	Refractory to weekly parenteral or oral methotrexate at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks AND Sulfasalazine 2g/day for at least 3 months	Refractory to weekly parenteral or oral methotrexate at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks AND Sulfasalazine 2g/day for at least 3 months

								least 3 months
Response Criteria	Improvement of at least 50% or 2 units in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score	To encourage uptake approvals will be valid indefinitely, with no renewal forms required.	Improvement of at least 50% or 2 units in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score	Improvement of at least 50% or 2 units in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score	Improvement of at least 50% or 2 units in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score	Not on formulary for this indication	To encourage uptake approvals will be valid indefinitely, with no renewal forms required.	Improvement of at least 50% or 2 units in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score

PSORIATIC ARTHRITIS

<u>Biologic/Biosimilar</u>	<u>Etanercept</u>	<u>Certolizumab Pegol</u>	<u>Adalimumab</u>	<u>Golimumab</u>	<u>Infliximab (Remicade)</u>	<u>Inflectra</u>	<u>Apremilast</u>	<u>Secukinumab</u>	<u>Ustekinumab</u>
Maximum Dose	50 mg weekly	400mg at weeks 0, 2, and 4, followed by 200mg every other week or 400mg every 4 weeks	40 mg q2weeks	50 mg monthly	Not on formulary for this indication	5 mg/kg, administered at 0, 2 and 6 weeks	Not on formulary for this indication	150 mg Weeks 0, 1, 2, 3, 4 and then 150 mg monthly If the patient is an anti-TNF inadequate responder and continues to have active PsA or has co-existent severe plaque psoriasis, 300 mg monthly will be considered	Not on formulary for this indication
Initial Criteria (1 year and prescribed by a rheumatologist)	At least two of the following: - 5 or more swollen joints; - if less than 5 swollen joints, at least one joint proximal to, or including wrist or ankle; - more than one joint with erosion on imaging study; - dactylitis of two or more digits; - tenosynovitis refractory to oral NSAIDs and steroid injections; - enthesitis refractory to oral NSAIDs and steroid injections (not required for	At least two of the following: - 5 or more swollen joints; - if less than 5 swollen joints, at least one joint proximal to, or including wrist or ankle; - more than one joint with erosion on imaging study; - dactylitis of two or more digits; - tenosynovitis refractory to oral NSAIDs and steroid injections; - enthesitis refractory to oral NSAIDs and steroid injections (not required for	At least two of the following: - 5 or more swollen joints; - if less than 5 swollen joints, at least one joint proximal to, or including wrist or ankle; - more than one joint with erosion on imaging study; - dactylitis of two or more digits; - tenosynovitis refractory to oral NSAIDs and steroid injections; - enthesitis refractory to oral NSAIDs and steroid injections (not required for	At least two of the following: - 5 or more swollen joints; - if less than 5 swollen joints, at least one joint proximal to, or including wrist or ankle; - more than one joint with erosion on imaging study; - dactylitis of two or more digits; - tenosynovitis refractory to oral NSAIDs and steroid injections; - enthesitis refractory to oral NSAIDs and steroid injections (not required for	Not on formulary for this indication	At least two of the following: - 5 or more swollen joints; - if less than 5 swollen joints, at least one joint proximal to, or including wrist or ankle; - more than one joint with erosion on imaging study; - dactylitis of two or more digits; - tenosynovitis refractory to oral NSAIDs and steroid injections; - enthesitis refractory to oral NSAIDs and steroid injections (not required for	Not on formulary for this indication	At least two of the following: - 5 or more swollen joints; - if less than 5 swollen joints, at least one joint proximal to, or including wrist or ankle; - more than one joint with erosion on imaging study; - dactylitis of two or more digits; - tenosynovitis refractory to oral NSAIDs and steroid injections; - enthesitis refractory to	Not on formulary for this indication

<p>Achilles tendon); - daily use of corticosteroids; - use of opioids > 12 hours per day for pain resulting from inflammation</p> <p>AND</p> <p>Refractory to a trial of at least 2 different NSAIDs at maximum tolerated doses for a combined total duration of 4 weeks</p> <p>AND a minimum of any two of the following:</p> <ul style="list-style-type: none"> - Methotrexate weekly oral or parenteral at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks - leflunomide: 20mg daily for 10 weeks - sulfasalazine at least 2g daily for 3 months - cyclosporine <p>OR</p> <p>AXIAL Disease with both of the following: BASDAI \geq 4 AND Refractory to a trial of at least 2 different NSAIDs at maximum tolerated doses</p>	<p>Achilles tendon); - daily use of corticosteroids; - use of opioids > 12 hours per day for pain resulting from inflammation</p> <p>AND</p> <p>Refractory to a trial of at least 2 different NSAIDs at maximum tolerated doses for a combined total duration of 4 weeks</p> <p>AND a minimum of any two of the following:</p> <ul style="list-style-type: none"> - Methotrexate weekly oral or parenteral at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks - leflunomide: 20mg daily for 10 weeks - sulfasalazine at least 2g daily for 3 months - cyclosporine <p>OR</p> <p>AXIAL Disease with both of the following: BASDAI \geq 4 AND Refractory to a trial of at least 2 different NSAIDs at maximum tolerated doses</p>	<p>Achilles tendon); - daily use of corticosteroids; - use of opioids > 12 hours per day for pain resulting from inflammation</p> <p>AND</p> <p>Refractory to a trial of at least 2 different NSAIDs at maximum tolerated doses for a combined total duration of 4 weeks</p> <p>AND a minimum of any two of the following:</p> <ul style="list-style-type: none"> - Methotrexate weekly oral or parenteral at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks - leflunomide: 20mg daily for 10 weeks - sulfasalazine at least 2g daily for 3 months - cyclosporine <p>OR</p> <p>AXIAL Disease with both of the following: BASDAI \geq 4 AND Refractory to a trial of at least 2 different NSAIDs at maximum tolerated doses</p>	<p>Achilles tendon); - daily use of corticosteroids; - use of opioids > 12 hours per day for pain resulting from inflammation</p> <p>AND</p> <p>Refractory to a trial of at least 2 different NSAIDs at maximum tolerated doses for a combined total duration of 4 weeks</p> <p>AND a minimum of any two of the following:</p> <ul style="list-style-type: none"> - Methotrexate weekly oral or parenteral at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks - leflunomide: 20mg daily for 10 weeks - sulfasalazine at least 2g daily for 3 months - cyclosporine <p>OR</p> <p>AXIAL Disease with both of the following: BASDAI \geq 4 AND Refractory to a trial of at least 2 different NSAIDs at maximum tolerated doses</p>	<p>Achilles tendon); - daily use of corticosteroids; - use of opioids > 12 hours per day for pain resulting from inflammation</p> <p>AND</p> <p>Refractory to a trial of at least 2 different NSAIDs at maximum tolerated doses for a combined total duration of 4 weeks</p> <p>AND a minimum of any two of the following:</p> <ul style="list-style-type: none"> - Methotrexate weekly oral or parenteral at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks - leflunomide: 20mg daily for 10 weeks - sulfasalazine at least 2g daily for 3 months - cyclosporine <p>OR</p> <p>AXIAL Disease with both of the following: BASDAI \geq 4 AND Refractory to a trial of at least 2 different NSAIDs at maximum tolerated doses</p>	<p>oral NSAIDs and steroid injections (not required for Achilles tendon); - daily use of corticosteroids;</p> <p>- use of opioids > 12 hours per day for pain resulting from inflammation</p> <p>AND</p> <p>Refractory to a trial of at least 2 different NSAIDs at maximum tolerated doses for a combined total duration of 4 weeks</p> <p>AND a minimum of any two of the following:</p> <ul style="list-style-type: none"> - Methotrexate weekly oral or parenteral at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks - leflunomide: 20mg daily for 10 weeks - sulfasalazine at least 2g daily for 3 months - cyclosporine
---	---	---	---	---	---

	for a combined total duration of 4 weeks	for a combined total duration of 4 weeks	for a combined total duration of 4 weeks	for a combined total duration of 4 weeks		for a combined total duration of 4 weeks		OR AXIAL Disease with both of the following: BASDAI \geq 4 AND Refractory to a trial of at least 2 different NSAIDs at maximum tolerated doses for a combined total duration of 4 weeks	
Response Criteria	Improvement in at least two of the four PsARC criteria, one of which has to be joint tenderness or swelling score, with no worsening in any of the four criteria. A response in joint count is determined by a reduction of \geq 30%. A response in the Physician or Patient Global Assessment scale is determined by a reduction of 1 point.	Improvement in at least two of the four PsARC criteria, one of which has to be joint tenderness or swelling score, with no worsening in any of the four criteria. A response in joint count is determined by a reduction of \geq 30%. A response in the Physician or Patient Global Assessment scale is determined by a reduction of 1 point.	Improvement in at least two of the four PsARC criteria, one of which has to be joint tenderness or swelling score, with no worsening in any of the four criteria. A response in joint count is determined by a reduction of \geq 30%. A response in the Physician or Patient Global Assessment scale is determined by a reduction of 1 point.	Improvement in at least two of the four PsARC criteria, one of which has to be joint tenderness or swelling score, with no worsening in any of the four criteria. A response in joint count is determined by a reduction of \geq 30%. A response in the Physician or Patient Global Assessment scale is determined by a reduction of 1 point.	Not on formulary for this indication	To encourage uptake of Inflectra, approvals will be valid indefinitely, with no renewal forms required.	Not on formulary for this indication	Improvement in at least two of the four PsARC criteria, one of which has to be joint tenderness or swelling score, with no worsening in any of the four criteria. A response in joint count is determined by a reduction of \geq 30%. A response in the Physician or Patient Global Assessment scale is determined by a reduction of 1 point.	Not on formulary for this indication

JUVENILE IDIOPATHIC ARTHRITIS

<u>Biologic/Biosimilar</u>	<u>Etanercept</u>	<u>Adalimumab</u>	<u>Tocilizumab</u>	<u>Abatacept</u>	<u>Canakinumab</u>
Maximum Dose	0.8 mg/kg/week body surface area up to a maximum single dose of 50 mg weekly	24 mg/m ² body surface area up to a maximum single dose of 40 mg every other week	<p>Polyarticular JIA: Coverage is initially provided for 16 weeks at a dose of 10 mg/kg once every four weeks for children weighing < 30 kg and 8 mg/kg for children weighing > 30 kg.</p> <p>Systemic JIA: Coverage is initially provided for 16 weeks at a dose of 12 mg/kg once every two weeks for children weighing < 30 kg and 8 mg/kg for children weighing > 30 kg.</p>	Coverage is initially provided for 16 weeks at a dose of 10 mg/kg for children <75 kg; 750 mg for children weighing 75 kg to 100 kg; and 1000 mg for children weighing >100kg.	Not on formulary for this indication
Initial Criteria (1 year and prescribed by a rheumatologist)	<p><u>POLYARTICULAR JIA</u></p> <p><u>Age ≥ 4 years</u></p> <ul style="list-style-type: none"> - ≥ 5 swollen joints; - ≥ 3 joints with limited range of motion and/or pain/tenderness; - Condition is refractory to an adequate trial of a therapeutic dose of methotrexate 	<p><u>POLYARTICULAR JIA</u></p> <p><u>Age ≥ 2 years</u></p> <ul style="list-style-type: none"> - ≥ 5 swollen joints; - ≥ 3 joints with limited range of motion and/or pain/tenderness; - Condition is refractory to an adequate trial of a therapeutic dose of methotrexate. 	<p><u>POLYARTICULAR JIA</u></p> <p><u>(Age ≥ 2 years)</u></p> <ul style="list-style-type: none"> - ≥ 5 swollen joints; - ≥ 3 joints with limited range of motion and/or pain/tenderness; - Condition is refractory to an adequate trial of a therapeutic dose of methotrexate <p><u>SYSTEMIC JIA (Age ≥ 2 years)</u></p> <p>Responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids (with or without methotrexate), due to intolerance or lack of efficacy.</p>	<p><u>POLYARTICULAR JIA</u></p> <p><u>Age ≥ 6 years</u></p> <ul style="list-style-type: none"> - ≥ 5 swollen joints; - ≥ 3 joints with limited range of motion and/or pain/tenderness; - Condition is refractory to an adequate trial of a therapeutic dose of methotrexate. 	Not on formulary for this indication
Response Criteria	<p>30% improvement in 3 of 6 clinical parameters:</p> <ul style="list-style-type: none"> • >30% reduction in the number of active joints • >30% reduction in the number of joints with loss 	<p>30% improvement in 3 of 6 clinical parameters:</p> <ul style="list-style-type: none"> • >30% reduction in the number of active joints • >30% reduction in the number of joints with loss 	<p>30% improvement in 3 of 6 clinical parameters:</p> <ul style="list-style-type: none"> • >30% reduction in the number of active joints • >30% reduction in the number of joints with loss of range of 	<p>30% improvement in 3 of 6 clinical parameters:</p> <ul style="list-style-type: none"> • >30% reduction in the number of active joints • >30% reduction in the number of joints with loss of range of 	Not on formulary for this indication

	<p>of range of motion</p> <ul style="list-style-type: none"> • >30% improvement in the Physician Global Assessment scale • >30% improvement in the Patient or Parent Global Assessment scale • >30% improvement in the Child Health Assessment Questionnaire (CHAQ) • >30% reduction in ESR <p>AND</p> <ul style="list-style-type: none"> • No more than one of these variables has worsened by greater than 30% 	<p>of range of motion</p> <ul style="list-style-type: none"> • >30% improvement in the Physician Global Assessment scale • >30% improvement in the Patient or Parent Global Assessment scale • >30% improvement in the Child Health Assessment Questionnaire (CHAQ) • >30% reduction in ESR <p>AND</p> <ul style="list-style-type: none"> • No more than one of these variables has worsened by greater than 30% 	<p>motion</p> <ul style="list-style-type: none"> • >30% improvement in the Physician Global Assessment scale • >30% improvement in the Patient or Parent Global Assessment scale • >30% improvement in the Child Health Assessment Questionnaire (CHAQ) • >30% reduction in ESR <p>AND</p> <ul style="list-style-type: none"> • No more than one of these variables has worsened by greater than 30% 	<p>motion</p> <ul style="list-style-type: none"> • >30% improvement in the Physician Global Assessment scale • >30% improvement in the Patient or Parent Global Assessment scale • >30% improvement in the Child Health Assessment Questionnaire (CHAQ) • >30% reduction in ESR <p>AND</p> <ul style="list-style-type: none"> • No more than one of these variables has worsened by greater than 30% 	
--	---	---	---	---	--

RHEUMATOID ARTHRITIS

<u>Biologic/ Biosimilar/ tsDMARD</u>	<u>Etanercept (Enbrel)</u>	<u>Etanercept (Brenzys)</u>	<u>Certolizuma b Pegol</u>	<u>Adalimumab</u>	<u>Golimumab</u>	<u>Inflixim ab (Remica de)</u>	<u>Inflectra</u>	<u>Tocilizumab IV or SC*</u>	<u>Tofacitinib</u>	<u>Rituxima b</u>	<u>Abatacept IV or SC</u>
Maximum Dose	50 mg weekly	50 mg weekly	400mg at weeks 0, 2, and 4, followed by 200mg every other week or 400mg every 4 weeks	40 mg q2weeks	50 mg monthly	Initial dose of 3 mg/kg at 0, 2 and 6 weeks	Initial dose of 3 mg/kg at 0, 2 and 6 weeks	IV: Coverage is initially provided for 16 weeks at an initial dose of 4 mg/kg/dose every 4 weeks. Max dose 8 mg/kg to a maximum of 800 mg every 4 weeks. SC: <100 kg: Initial approval is for 162 mg every other week, can request up to a maximum of 162 mg every week (maximum 51 doses) >100 kg: 162 mg weekly (maximum 52 doses)	10 mg daily	1000 mg x 2 doses at 0 & 2 weeks	IV: Weeks 0, 2 and 4 then every 4 weeks 500 mg IV if <60 kg; 750 mg IV if 60-100 kg; 1000 mg IV if >100 kg SC: 1 IV dose load then 125 mg weekly
Initial Criteria (1 year and prescribed by a rheumatologist; for ≥ 18 years of age)	In combination with MTX or other DMARDs Refractory to - MTX (oral or parenteral at a dose ≥	In combination with MTX or other DMARDs Refractory to - MTX (oral or parenteral at a dose ≥	In combination with MTX or other DMARDs Refractory to - MTX (oral or parenteral at a dose ≥	In combination with MTX or other DMARDs Refractory to - MTX (oral or parenteral at a dose ≥	In combination with MTX or other DMARDs Refractory to - MTX (oral or parenteral at a dose ≥	As of May 1 2017, all new requests for infliximab will be provided with inflectra	In combination with MTX or other DMARDs Refractory to - MTX (oral or parenteral at a dose ≥	In combination with MTX or other DMARDs Refractory to - MTX (oral or parenteral at a dose ≥	In combination with MTX or other DMARDs Refractory to - MTX (oral or parenteral at a dose ≥	Refractory to - anti-TNF Recommended to be used in combination with MTX or	In combination with MTX or other DMARDs Refractory to - MTX (oral or parenteral at a dose ≥

											DMARDs, such as sulfasalazine, hydroxychloroquine, azathioprine, leflunomide, cyclosporine or gold, for a minimum of 12 weeks of continuous treatment
Response Criteria	<p>20% improvement in 3 of 5 clinical parameters:</p> <p>>20% reduction in number of tender and swollen joints</p> <p>AND</p> <p>>20% improvement in physician global assessment scale</p> <p>AND</p> <p>>20% improvement in the patient global assessment scale</p> <p>OR⁽¹⁾_(SEP)</p> <p>>20% reduction in the acute phase as measured by</p>	<p>To encourage uptake approvals will be valid indefinitely, with no renewal forms required.</p>	<p>20% improvement in 3 of 5 clinical parameters:</p> <p>>20% reduction in number of tender and swollen joints</p> <p>AND</p> <p>>20% improvement in physician global assessment scale</p> <p>AND</p> <p>>20% improvement in the patient global assessment scale</p> <p>OR⁽¹⁾_(SEP)</p> <p>>20% reduction in the acute phase as measured by</p>	<p>20% improvement in 3 of 5 clinical parameters:</p> <p>>20% reduction in number of tender and swollen joints</p> <p>AND</p> <p>>20% improvement in physician global assessment scale</p> <p>AND</p> <p>>20% improvement in the patient global assessment scale</p> <p>OR⁽¹⁾_(SEP)</p> <p>>20% reduction in the acute phase as measured by</p>	<p>20% improvement in 3 of 5 clinical parameters:</p> <p>>20% reduction in number of tender and swollen joints</p> <p>AND</p> <p>>20% improvement in physician global assessment scale</p> <p>AND</p> <p>>20% improvement in the patient global assessment scale</p> <p>OR⁽¹⁾_(SEP)</p> <p>>20% reduction in the acute phase as measured by</p>	<p>20% improvement in 3 of 5 clinical parameters:</p> <p>>20% reduction in number of tender and swollen joints</p> <p>AND</p> <p>>20% improvement in physician global assessment scale</p> <p>AND</p> <p>>20% improvement in the patient global assessment scale</p> <p>OR⁽¹⁾_(SEP)</p> <p>>20% reduction in the acute phase as measured by</p>	<p>To encourage uptake of Inflectra, approvals will be valid indefinitely, with no renewal forms required.</p>	<p>20% improvement from baseline in swollen and tender joint counts, plus a 20% improvement in 2 of 5 baseline clinical parameters.</p> <p>• >20% reduction in number of tender and swollen joints</p> <p>AND</p> <p>>20% improvement in physician global assessment scale</p> <p>AND</p> <p>>20% improvement in the patient global assessment scale</p> <p>OR</p> <p>• >20% improvement in Physician Global Assessment scale; PLUS either</p> <p>• >20% improvement in Patient Global Assessment scale; OR</p> <p>• >20% reduction in the acute phase as measured by</p>	<p>20% improvement in 3 of 5 baseline clinical parameters:</p> <p>>20% reduction in number of tender and swollen joints</p> <p>AND</p> <p>>20% improvement in physician global assessment scale</p> <p>AND</p> <p>>20% improvement in the patient global assessment scale</p> <p>OR⁽¹⁾_(SEP)</p> <p>>20% reduction in the acute phase as</p>	<p>Assess between 20 and 24 weeks for:</p> <p>>20% reduction in number of tender and swollen joints⁽¹⁾_(SEP)</p> <p>AND</p> <p>>20% improvement in physician global assessment scale</p> <p>AND</p> <p>>20% improvement in the patient global assessment scale</p> <p>OR</p> <p>>20% reduction</p>	<p>Coverage beyond one year will be based on a 20% improvement in 3 of 5 clinical parameters:</p> <p>>20% reduction in number of tender and swollen joints</p> <p>AND</p> <p>>20% improvement in physician global assessment scale</p> <p>AND</p> <p>>20% improvement in the patient global assessment scale</p> <p>OR⁽¹⁾_(SEP)</p> <p>>20%</p>

	ESR or CRP		ESR or CRP	ESR or CRP	ESR or CRP	ent scale OR ^{ESR} _{CRP} >20% reduction in the acute phase as measured by ESR or CRP		ESR or CRP. SC – as per other agents	measured by ESR or CRP	in the acute phase as measured by ESR or CRP.	reduction in the acute phase as measured by ESR or CRP
--	------------	--	------------	------------	------------	--	--	---	------------------------	---	--

Biologics for Granulomatosis with Polyangiitis or Microscopic Polyangiitis

Rituximab is provided at a dose of 375 mg/m² body surface area, weekly x 4 weeks, for induction of remission in patients with severely active disease AND who have failed an adequate trial of cyclophosphamide OR who have a contraindication to cyclophosphamide.

Biologics for Systemic Lupus Erythematosus

BELIMUMAB – is not a benefit

Limited Use Gout Therapy

FEBUXOSTAT
Prior approval required

For patients with symptomatic gout who have documented hypersensitivity to allopurinol

Limited Use Osteoporosis Therapy

Agent	Criteria
DENOSUMAB / PROLIA	For women with postmenopausal osteoporosis who have failed or have a contraindication to bisphosphonates due to hypersensitivity or abnormalities of the esophagus (e.g., esophageal stricture or achalasia); AND who have at least two of the following: • age >70 years • a prior fragility fracture • a bone mineral density (BMD) T-score ≤ -2.5

	Maximum dose covered is 60mg per 6-month period.
ZOLEDRONIC ACID	For the treatment of Paget's disease. Coverage will be granted for one dose per 12 month period; OR For women with postmenopausal osteoporosis who would otherwise be eligible for coverage of oral bisphosphonates, but who have a contraindication to bisphosphonates due to hypersensitivity or abnormalities of the esophagus (e.g., esophageal stricture or achalasia); AND who have at least two of the following: • age >70 years • a prior fragility fracture • a bone mineral density (BMD) T-score ≤ - 2.5.

Effective March 10, 2016, the following bisphosphonates became an open benefit:

Risedronate 5 mg, 30 mg, 35 mg and 150 mg Alendronate 5 mg, 10 mg, 40 mg and 70 mg Alendronate/vitamin D3

This change is intended to increase client access to medications for the treatment and prevention of osteoporosis and Paget disease.

Limited Use Pulmonary Arterial Hypertension Therapy

SILDENAFIL, TADALAFIL

Prior approval required and must be initiated by a Pulmonary Hypertension specialist.

Patients with World Health Organization (WHO) class III pulmonary artery hypertension (PAH), either idiopathic (i.e. primary) or associated with a congenital or systemic condition (e.g. connective tissue disease) and confirmed by right heart catheterization;

AMBRISSENTEN (Maximum dose covered is 10 mg once daily): as above for patients with PAH, but who have failed to respond to sildenafil OR tadalafil; OR who have contraindications to sildenafil OR tadalafil.

BOSENTEN (Maximum dose covered is 125 mg twice daily): as above for patients with PAH, but who have failed to respond to sildenafil OR tadalafil; OR who have contraindications to sildenafil OR tadalafil.

Limited Use – Pediatrics Miscellaneous

ASA

ASA 80 mg tablets are a benefit to clients age 21 years and under to allow access for use in pediatric conditions (e.g. Kawasaki Syndrome).

Limited Use Analgesic Therapies

DICLOFENAC SODIUM 1.5% TOPICAL SOLUTION (PMS-Diclofenac DIN 02356783, Diclofenac topical DIN 02434571, Taro-Diclofenac DIN 02420988) and COMPOUND SOLUTIONS

Limited use benefit (prior approval required – pharmacist contacts DEC for approval).

For the treatment of osteoarthritis when:

a. Pain is inadequately controlled with acetaminophen AND a non-steroidal anti-inflammatory (NSAID) OR b. There is contraindication to acetaminophen and NSAID OR ¹¹OR ¹²OR ¹³OR ¹⁴OR ¹⁵OR ¹⁶OR ¹⁷OR ¹⁸OR ¹⁹OR ²⁰OR ²¹OR ²²OR ²³OR ²⁴OR ²⁵OR ²⁶OR ²⁷OR ²⁸OR ²⁹OR ³⁰OR ³¹OR ³²OR ³³OR ³⁴OR ³⁵OR ³⁶OR ³⁷OR ³⁸OR ³⁹OR ⁴⁰OR ⁴¹OR ⁴²OR ⁴³OR ⁴⁴OR ⁴⁵OR ⁴⁶OR ⁴⁷OR ⁴⁸OR ⁴⁹OR ⁵⁰OR ⁵¹OR ⁵²OR ⁵³OR ⁵⁴OR ⁵⁵OR ⁵⁶OR ⁵⁷OR ⁵⁸OR ⁵⁹OR ⁶⁰OR ⁶¹OR ⁶²OR ⁶³OR ⁶⁴OR ⁶⁵OR ⁶⁶OR ⁶⁷OR ⁶⁸OR ⁶⁹OR ⁷⁰OR ⁷¹OR ⁷²OR ⁷³OR ⁷⁴OR ⁷⁵OR ⁷⁶OR ⁷⁷OR ⁷⁸OR ⁷⁹OR ⁸⁰OR ⁸¹OR ⁸²OR ⁸³OR ⁸⁴OR ⁸⁵OR ⁸⁶OR ⁸⁷OR ⁸⁸OR ⁸⁹OR ⁹⁰OR ⁹¹OR ⁹²OR ⁹³OR ⁹⁴OR ⁹⁵OR ⁹⁶OR ⁹⁷OR ⁹⁸OR ⁹⁹OR ¹⁰⁰OR ¹⁰¹OR ¹⁰²OR ¹⁰³OR ¹⁰⁴OR ¹⁰⁵OR ¹⁰⁶OR ¹⁰⁷OR ¹⁰⁸OR ¹⁰⁹OR ¹¹⁰OR ¹¹¹OR ¹¹²OR ¹¹³OR ¹¹⁴OR ¹¹⁵OR ¹¹⁶OR ¹¹⁷OR ¹¹⁸OR ¹¹⁹OR ¹²⁰OR ¹²¹OR ¹²²OR ¹²³OR ¹²⁴OR ¹²⁵OR ¹²⁶OR ¹²⁷OR ¹²⁸OR ¹²⁹OR ¹³⁰OR ¹³¹OR ¹³²OR ¹³³OR ¹³⁴OR ¹³⁵OR ¹³⁶OR ¹³⁷OR ¹³⁸OR ¹³⁹OR ¹⁴⁰OR ¹⁴¹OR ¹⁴²OR ¹⁴³OR ¹⁴⁴OR ¹⁴⁵OR ¹⁴⁶OR ¹⁴⁷OR ¹⁴⁸OR ¹⁴⁹OR ¹⁵⁰OR ¹⁵¹OR ¹⁵²OR ¹⁵³OR ¹⁵⁴OR ¹⁵⁵OR ¹⁵⁶OR ¹⁵⁷OR ¹⁵⁸OR ¹⁵⁹OR ¹⁶⁰OR ¹⁶¹OR ¹⁶²OR ¹⁶³OR ¹⁶⁴OR ¹⁶⁵OR ¹⁶⁶OR ¹⁶⁷OR ¹⁶⁸OR ¹⁶⁹OR ¹⁷⁰OR ¹⁷¹OR ¹⁷²OR ¹⁷³OR ¹⁷⁴OR ¹⁷⁵OR ¹⁷⁶OR ¹⁷⁷OR ¹⁷⁸OR ¹⁷⁹OR ¹⁸⁰OR ¹⁸¹OR ¹⁸²OR ¹⁸³OR ¹⁸⁴OR ¹⁸⁵OR ¹⁸⁶OR ¹⁸⁷OR ¹⁸⁸OR ¹⁸⁹OR ¹⁹⁰OR ¹⁹¹OR ¹⁹²OR ¹⁹³OR ¹⁹⁴OR ¹⁹⁵OR ¹⁹⁶OR ¹⁹⁷OR ¹⁹⁸OR ¹⁹⁹OR ²⁰⁰OR ²⁰¹OR ²⁰²OR ²⁰³OR ²⁰⁴OR ²⁰⁵OR ²⁰⁶OR ²⁰⁷OR ²⁰⁸OR ²⁰⁹OR ²¹⁰OR ²¹¹OR ²¹²OR ²¹³OR ²¹⁴OR ²¹⁵OR ²¹⁶OR ²¹⁷OR ²¹⁸OR ²¹⁹OR ²²⁰OR ²²¹OR ²²²OR ²²³OR ²²⁴OR ²²⁵OR ²²⁶OR ²²⁷OR ²²⁸OR ²²⁹OR ²³⁰OR ²³¹OR ²³²OR ²³³OR ²³⁴OR ²³⁵OR ²³⁶OR ²³⁷OR ²³⁸OR ²³⁹OR ²⁴⁰OR ²⁴¹OR ²⁴²OR ²⁴³OR ²⁴⁴OR ²⁴⁵OR ²⁴⁶OR ²⁴⁷OR ²⁴⁸OR ²⁴⁹OR ²⁵⁰OR ²⁵¹OR ²⁵²OR ²⁵³OR ²⁵⁴OR ²⁵⁵OR ²⁵⁶OR ²⁵⁷OR ²⁵⁸OR ²⁵⁹OR ²⁶⁰OR ²⁶¹OR ²⁶²OR ²⁶³OR ²⁶⁴OR ²⁶⁵OR ²⁶⁶OR ²⁶⁷OR ²⁶⁸OR ²⁶⁹OR ²⁷⁰OR ²⁷¹OR ²⁷²OR ²⁷³OR ²⁷⁴OR ²⁷⁵OR ²⁷⁶OR ²⁷⁷OR ²⁷⁸OR ²⁷⁹OR ²⁸⁰OR ²⁸¹OR ²⁸²OR ²⁸³OR ²⁸⁴OR ²⁸⁵OR ²⁸⁶OR ²⁸⁷OR ²⁸⁸OR ²⁸⁹OR ²⁹⁰OR ²⁹¹OR ²⁹²OR ²⁹³OR ²⁹⁴OR ²⁹⁵OR ²⁹⁶OR ²⁹⁷OR ²⁹⁸OR ²⁹⁹OR ³⁰⁰OR ³⁰¹OR ³⁰²OR ³⁰³OR ³⁰⁴OR ³⁰⁵OR ³⁰⁶OR ³⁰⁷OR ³⁰⁸OR ³⁰⁹OR ³¹⁰OR ³¹¹OR ³¹²OR ³¹³OR ³¹⁴OR ³¹⁵OR ³¹⁶OR ³¹⁷OR ³¹⁸OR ³¹⁹OR ³²⁰OR ³²¹OR ³²²OR ³²³OR ³²⁴OR ³²⁵OR ³²⁶OR ³²⁷OR ³²⁸OR ³²⁹OR ³³⁰OR ³³¹OR ³³²OR ³³³OR ³³⁴OR ³³⁵OR ³³⁶OR ³³⁷OR ³³⁸OR ³³⁹OR ³⁴⁰OR ³⁴¹OR ³⁴²OR ³⁴³OR ³⁴⁴OR ³⁴⁵OR ³⁴⁶OR ³⁴⁷OR ³⁴⁸OR ³⁴⁹OR ³⁵⁰OR ³⁵¹OR ³⁵²OR ³⁵³OR ³⁵⁴OR ³⁵⁵OR ³⁵⁶OR ³⁵⁷OR ³⁵⁸OR ³⁵⁹OR ³⁶⁰OR ³⁶¹OR ³⁶²OR ³⁶³OR ³⁶⁴OR ³⁶⁵OR ³⁶⁶OR ³⁶⁷OR ³⁶⁸OR ³⁶⁹OR ³⁷⁰OR ³⁷¹OR ³⁷²OR ³⁷³OR ³⁷⁴OR ³⁷⁵OR ³⁷⁶OR ³⁷⁷OR ³⁷⁸OR ³⁷⁹OR ³⁸⁰OR ³⁸¹OR ³⁸²OR ³⁸³OR ³⁸⁴OR ³⁸⁵OR ³⁸⁶OR ³⁸⁷OR ³⁸⁸OR ³⁸⁹OR ³⁹⁰OR ³⁹¹OR ³⁹²OR ³⁹³OR ³⁹⁴OR ³⁹⁵OR ³⁹⁶OR ³⁹⁷OR ³⁹⁸OR ³⁹⁹OR ⁴⁰⁰OR ⁴⁰¹OR ⁴⁰²OR ⁴⁰³OR ⁴⁰⁴OR ⁴⁰⁵OR ⁴⁰⁶OR ⁴⁰⁷OR ⁴⁰⁸OR ⁴⁰⁹OR ⁴¹⁰OR ⁴¹¹OR ⁴¹²OR ⁴¹³OR ⁴¹⁴OR ⁴¹⁵OR ⁴¹⁶OR ⁴¹⁷OR ⁴¹⁸OR ⁴¹⁹OR ⁴²⁰OR ⁴²¹OR ⁴²²OR ⁴²³OR ⁴²⁴OR ⁴²⁵OR ⁴²⁶OR ⁴²⁷OR ⁴²⁸OR ⁴²⁹OR ⁴³⁰OR ⁴³¹OR ⁴³²OR ⁴³³OR ⁴³⁴OR ⁴³⁵OR ⁴³⁶OR ⁴³⁷OR ⁴³⁸OR ⁴³⁹OR ⁴⁴⁰OR ⁴⁴¹OR ⁴⁴²OR ⁴⁴³OR ⁴⁴⁴OR ⁴⁴⁵OR ⁴⁴⁶OR ⁴⁴⁷OR ⁴⁴⁸OR ⁴⁴⁹OR ⁴⁵⁰OR ⁴⁵¹OR ⁴⁵²OR ⁴⁵³OR ⁴⁵⁴OR ⁴⁵⁵OR ⁴⁵⁶OR ⁴⁵⁷OR ⁴⁵⁸OR ⁴⁵⁹OR ⁴⁶⁰OR ⁴⁶¹OR ⁴⁶²OR ⁴⁶³OR ⁴⁶⁴OR ⁴⁶⁵OR ⁴⁶⁶OR ⁴⁶⁷OR ⁴⁶⁸OR ⁴⁶⁹OR ⁴⁷⁰OR ⁴⁷¹OR ⁴⁷²OR ⁴⁷³OR ⁴⁷⁴OR ⁴⁷⁵OR ⁴⁷⁶OR ⁴⁷⁷OR ⁴⁷⁸OR ⁴⁷⁹OR ⁴⁸⁰OR ⁴⁸¹OR ⁴⁸²OR ⁴⁸³OR ⁴⁸⁴OR ⁴⁸⁵OR ⁴⁸⁶OR ⁴⁸⁷OR ⁴⁸⁸OR ⁴⁸⁹OR ⁴⁹⁰OR ⁴⁹¹OR ⁴⁹²OR ⁴⁹³OR ⁴⁹⁴OR ⁴⁹⁵OR ⁴⁹⁶OR ⁴⁹⁷OR ⁴⁹⁸OR ⁴⁹⁹OR ⁵⁰⁰OR ⁵⁰¹OR ⁵⁰²OR ⁵⁰³OR ⁵⁰⁴OR ⁵⁰⁵OR ⁵⁰⁶OR ⁵⁰⁷OR ⁵⁰⁸OR ⁵⁰⁹OR ⁵¹⁰OR ⁵¹¹OR ⁵¹²OR ⁵¹³OR ⁵¹⁴OR ⁵¹⁵OR ⁵¹⁶OR ⁵¹⁷OR ⁵¹⁸OR ⁵¹⁹OR ⁵²⁰OR ⁵²¹OR ⁵²²OR ⁵²³OR ⁵²⁴OR ⁵²⁵OR ⁵²⁶OR ⁵²⁷OR ⁵²⁸OR ⁵²⁹OR ⁵³⁰OR ⁵³¹OR ⁵³²OR ⁵³³OR ⁵³⁴OR ⁵³⁵OR ⁵³⁶OR ⁵³⁷OR ⁵³⁸OR ⁵³⁹OR ⁵⁴⁰OR ⁵⁴¹OR ⁵⁴²OR ⁵⁴³OR ⁵⁴⁴OR ⁵⁴⁵OR ⁵⁴⁶OR ⁵⁴⁷OR ⁵⁴⁸OR ⁵⁴⁹OR ⁵⁵⁰OR ⁵⁵¹OR ⁵⁵²OR ⁵⁵³OR ⁵⁵⁴OR ⁵⁵⁵OR ⁵⁵⁶OR ⁵⁵⁷OR ⁵⁵⁸OR ⁵⁵⁹OR ⁵⁶⁰OR ⁵⁶¹OR ⁵⁶²OR ⁵⁶³OR ⁵⁶⁴OR ⁵⁶⁵OR ⁵⁶⁶OR ⁵⁶⁷OR ⁵⁶⁸OR ⁵⁶⁹OR ⁵⁷⁰OR ⁵⁷¹OR ⁵⁷²OR ⁵⁷³OR ⁵⁷⁴OR ⁵⁷⁵OR ⁵⁷⁶OR ⁵⁷⁷OR ⁵⁷⁸OR ⁵⁷⁹OR ⁵⁸⁰OR ⁵⁸¹OR ⁵⁸²OR ⁵⁸³OR ⁵⁸⁴OR ⁵⁸⁵OR ⁵⁸⁶OR ⁵⁸⁷OR ⁵⁸⁸OR ⁵⁸⁹OR ⁵⁹⁰OR ⁵⁹¹OR ⁵⁹²OR ⁵⁹³OR ⁵⁹⁴OR ⁵⁹⁵OR ⁵⁹⁶OR ⁵⁹⁷OR ⁵⁹⁸OR ⁵⁹⁹OR ⁶⁰⁰OR ⁶⁰¹OR ⁶⁰²OR ⁶⁰³OR ⁶⁰⁴OR ⁶⁰⁵OR ⁶⁰⁶OR ⁶⁰⁷OR ⁶⁰⁸OR ⁶⁰⁹OR ⁶¹⁰OR ⁶¹¹OR ⁶¹²OR ⁶¹³OR ⁶¹⁴OR ⁶¹⁵OR ⁶¹⁶OR ⁶¹⁷OR ⁶¹⁸OR ⁶¹⁹OR ⁶²⁰OR ⁶²¹OR ⁶²²OR ⁶²³OR ⁶²⁴OR ⁶²⁵OR ⁶²⁶OR ⁶²⁷OR ⁶²⁸OR ⁶²⁹OR ⁶³⁰OR ⁶³¹OR ⁶³²OR ⁶³³OR ⁶³⁴OR ⁶³⁵OR ⁶³⁶OR ⁶³⁷OR ⁶³⁸OR ⁶³⁹OR ⁶⁴⁰OR ⁶⁴¹OR ⁶⁴²OR ⁶⁴³OR ⁶⁴⁴OR ⁶⁴⁵OR ⁶⁴⁶OR ⁶⁴⁷OR ⁶⁴⁸OR ⁶⁴⁹OR ⁶⁵⁰OR ⁶⁵¹OR ⁶⁵²OR ⁶⁵³OR ⁶⁵⁴OR ⁶⁵⁵OR ⁶⁵⁶OR ⁶⁵⁷OR ⁶⁵⁸OR ⁶⁵⁹OR ⁶⁶⁰OR ⁶⁶¹OR ⁶⁶²OR ⁶⁶³OR ⁶⁶⁴OR ⁶⁶⁵OR ⁶⁶⁶OR ⁶⁶⁷OR ⁶⁶⁸OR ⁶⁶⁹OR ⁶⁷⁰OR ⁶⁷¹OR ⁶⁷²OR ⁶⁷³OR ⁶⁷⁴OR ⁶⁷⁵OR ⁶⁷⁶OR ⁶⁷⁷OR ⁶⁷⁸OR ⁶⁷⁹OR ⁶⁸⁰OR ⁶⁸¹OR ⁶⁸²OR ⁶⁸³OR ⁶⁸⁴OR ⁶⁸⁵OR ⁶⁸⁶OR ⁶⁸⁷OR ⁶⁸⁸OR ⁶⁸⁹OR ⁶⁹⁰OR ⁶⁹¹OR ⁶⁹²OR ⁶⁹³OR ⁶⁹⁴OR ⁶⁹⁵OR ⁶⁹⁶OR ⁶⁹⁷OR ⁶⁹⁸OR ⁶⁹⁹OR ⁷⁰⁰OR ⁷⁰¹OR ⁷⁰²OR ⁷⁰³OR ⁷⁰⁴OR ⁷⁰⁵OR ⁷⁰⁶OR ⁷⁰⁷OR ⁷⁰⁸OR ⁷⁰⁹OR ⁷¹⁰OR ⁷¹¹OR ⁷¹²OR ⁷¹³OR ⁷¹⁴OR ⁷¹⁵OR ⁷¹⁶OR ⁷¹⁷OR ⁷¹⁸OR ⁷¹⁹OR ⁷²⁰OR ⁷²¹OR ⁷²²OR ⁷²³OR ⁷²⁴OR ⁷²⁵OR ⁷²⁶OR ⁷²⁷OR ⁷²⁸OR ⁷²⁹OR ⁷³⁰OR ⁷³¹OR ⁷³²OR ⁷³³OR ⁷³⁴OR ⁷³⁵OR ⁷³⁶OR ⁷³⁷OR ⁷³⁸OR ⁷³⁹OR ⁷⁴⁰OR ⁷⁴¹OR ⁷⁴²OR ⁷⁴³OR ⁷⁴⁴OR ⁷⁴⁵OR ⁷⁴⁶OR ⁷⁴⁷OR ⁷⁴⁸OR ⁷⁴⁹OR ⁷⁵⁰OR ⁷⁵¹OR ⁷⁵²OR ⁷⁵³OR ⁷⁵⁴OR ⁷⁵⁵OR ⁷⁵⁶OR ⁷⁵⁷OR ⁷⁵⁸OR ⁷⁵⁹OR ⁷⁶⁰OR ⁷⁶¹OR ⁷⁶²OR ⁷⁶³OR ⁷⁶⁴OR ⁷⁶⁵OR ⁷⁶⁶OR ⁷⁶⁷OR ⁷⁶⁸OR ⁷⁶⁹OR ⁷⁷⁰OR ⁷⁷¹OR ⁷⁷²OR ⁷⁷³OR ⁷⁷⁴OR ⁷⁷⁵OR ⁷⁷⁶OR ⁷⁷⁷OR ⁷⁷⁸OR ⁷⁷⁹OR ⁷⁸⁰OR ⁷⁸¹OR ⁷⁸²OR ⁷⁸³OR ⁷⁸⁴OR ⁷⁸⁵OR ⁷⁸⁶OR ⁷⁸⁷OR ⁷⁸⁸OR ⁷⁸⁹OR ⁷⁹⁰OR ⁷⁹¹OR ⁷⁹²OR ⁷⁹³OR ⁷⁹⁴OR ⁷⁹⁵OR ⁷⁹⁶OR ⁷⁹⁷OR ⁷⁹⁸OR ⁷⁹⁹OR ⁸⁰⁰OR ⁸⁰¹OR ⁸⁰²OR ⁸⁰³OR ⁸⁰⁴OR ⁸⁰⁵OR ⁸⁰⁶OR ⁸⁰⁷OR ⁸⁰⁸OR ⁸⁰⁹OR ⁸¹⁰OR ⁸¹¹OR ⁸¹²OR ⁸¹³OR ⁸¹⁴OR ⁸¹⁵OR ⁸¹⁶OR ⁸¹⁷OR ⁸¹⁸OR ⁸¹⁹OR ⁸²⁰OR ⁸²¹OR ⁸²²OR ⁸²³OR ⁸²⁴OR ⁸²⁵OR ⁸²⁶OR ⁸²⁷OR ⁸²⁸OR ⁸²⁹OR ⁸³⁰OR ⁸³¹OR ⁸³²OR ⁸³³OR ⁸³⁴OR ⁸³⁵OR ⁸³⁶OR ⁸³⁷OR ⁸³⁸OR ⁸³⁹OR ⁸⁴⁰OR ⁸⁴¹OR ⁸⁴²OR ⁸⁴³OR ⁸⁴⁴OR ⁸⁴⁵OR ⁸⁴⁶OR ⁸⁴⁷OR ⁸⁴⁸OR ⁸⁴⁹OR ⁸⁵⁰OR ⁸⁵¹OR ⁸⁵²OR ⁸⁵³OR ⁸⁵⁴OR ⁸⁵⁵OR ⁸⁵⁶OR ⁸⁵⁷OR ⁸⁵⁸OR ⁸⁵⁹OR ⁸⁶⁰OR ⁸⁶¹OR ⁸⁶²OR ⁸⁶³OR ⁸⁶⁴OR ⁸⁶⁵OR ⁸⁶⁶OR ⁸⁶⁷OR ⁸⁶⁸OR ⁸⁶⁹OR ⁸⁷⁰OR ⁸⁷¹OR ⁸⁷²OR ⁸⁷³OR ⁸⁷⁴OR ⁸⁷⁵OR ⁸⁷⁶OR ⁸⁷⁷OR ⁸⁷⁸OR ⁸⁷⁹OR ⁸⁸⁰OR ⁸⁸¹OR ⁸⁸²OR ⁸⁸³OR ⁸⁸⁴OR ⁸⁸⁵OR ⁸⁸⁶OR ⁸⁸⁷OR ⁸⁸⁸OR ⁸⁸⁹OR ⁸⁹⁰OR ⁸⁹¹OR ⁸⁹²OR ⁸⁹³OR ⁸⁹⁴OR ⁸⁹⁵OR ⁸⁹⁶OR ⁸⁹⁷OR ⁸⁹⁸OR ⁸⁹⁹OR ⁹⁰⁰OR ⁹⁰¹OR ⁹⁰²OR ⁹⁰³OR ⁹⁰⁴OR ⁹⁰⁵OR ⁹⁰⁶OR ⁹⁰⁷OR ⁹⁰⁸OR ⁹⁰⁹OR ⁹¹⁰OR ⁹¹¹OR ⁹¹²OR ⁹¹³OR ⁹¹⁴OR ⁹¹⁵OR ⁹¹⁶OR ⁹¹⁷OR ⁹¹⁸OR ⁹¹⁹OR ⁹²⁰OR ⁹²¹OR ⁹²²OR ⁹²³OR ⁹²⁴OR ⁹²⁵OR ⁹²⁶OR ⁹²⁷OR ⁹²⁸OR ⁹²⁹OR ⁹³⁰OR ⁹³¹OR ⁹³²OR ⁹³³OR ⁹³⁴OR ⁹³⁵OR ⁹³⁶OR ⁹³⁷OR ⁹³⁸OR ⁹³⁹OR ⁹⁴⁰OR ⁹⁴¹OR ⁹⁴²OR ⁹⁴³OR ⁹⁴⁴OR ⁹⁴⁵OR ⁹⁴⁶OR ⁹⁴⁷OR ⁹⁴⁸OR ⁹⁴⁹OR ⁹⁵⁰OR ⁹⁵¹OR ⁹⁵²OR ⁹⁵³OR ⁹⁵⁴OR ⁹⁵⁵OR ⁹⁵⁶OR ⁹⁵⁷OR ⁹⁵⁸OR ⁹⁵⁹OR ⁹⁶⁰OR ⁹⁶¹OR ⁹⁶²OR ⁹⁶³OR ⁹⁶⁴OR ⁹⁶⁵OR ⁹⁶⁶OR ⁹⁶⁷OR ⁹⁶⁸OR ⁹⁶⁹OR ⁹⁷⁰OR ⁹⁷¹OR ⁹⁷²OR ⁹⁷³OR ⁹⁷⁴OR ⁹⁷⁵OR ⁹⁷⁶OR ⁹⁷⁷OR ⁹⁷⁸OR ⁹⁷⁹OR ⁹⁸⁰OR ⁹⁸¹OR ⁹⁸²OR ⁹⁸³OR ⁹⁸⁴OR ⁹⁸⁵OR ⁹⁸⁶OR ⁹⁸⁷OR ⁹⁸⁸OR ⁹⁸⁹OR ⁹⁹⁰OR ⁹⁹¹OR ⁹⁹²OR ⁹⁹³OR ⁹⁹⁴OR ⁹⁹⁵OR ⁹⁹⁶OR ⁹⁹⁷OR ⁹⁹⁸OR ⁹⁹⁹OR ¹⁰⁰⁰OR ¹⁰⁰¹OR ¹⁰⁰²OR ¹⁰⁰³OR ¹⁰⁰⁴OR ¹⁰⁰⁵OR ¹⁰⁰⁶OR ¹⁰⁰⁷OR ¹⁰⁰⁸OR ¹⁰⁰⁹OR ¹⁰¹⁰OR ¹⁰¹¹OR ¹⁰¹²OR ¹⁰¹³OR ¹⁰¹⁴OR ¹⁰¹⁵OR ¹⁰¹⁶OR ¹⁰¹⁷OR ¹⁰¹⁸OR ¹⁰¹⁹OR ¹⁰²⁰OR ¹⁰²¹OR ¹⁰²²OR ¹⁰²³OR ¹⁰²⁴OR ¹⁰²⁵OR ¹⁰²⁶OR ¹⁰²⁷OR ¹⁰²⁸OR ¹⁰²⁹OR ¹⁰³⁰OR ¹⁰³¹OR ¹⁰³²OR ¹⁰³³OR ¹⁰³⁴OR ¹⁰³⁵OR ¹⁰³⁶OR ¹⁰³⁷OR ¹⁰³⁸OR ¹⁰³⁹OR ¹⁰⁴⁰OR ¹⁰⁴¹OR ¹⁰⁴²OR ¹⁰⁴³OR ¹⁰⁴⁴OR ¹⁰⁴⁵OR ¹⁰⁴⁶OR ¹⁰⁴⁷OR ¹⁰⁴⁸OR ¹⁰⁴⁹OR ¹⁰⁵⁰OR ¹⁰⁵¹OR ¹⁰⁵²OR ¹⁰⁵³OR ¹⁰⁵⁴OR ¹⁰⁵⁵OR ¹⁰⁵⁶OR ¹⁰⁵⁷OR ¹⁰⁵⁸OR ¹⁰⁵⁹OR ¹⁰⁶⁰OR ¹⁰⁶¹OR ¹⁰⁶²OR ¹⁰⁶³OR ¹⁰⁶⁴OR ¹⁰⁶⁵OR ¹⁰⁶⁶OR ¹⁰⁶⁷OR ¹⁰⁶⁸OR ¹⁰⁶⁹OR ¹⁰⁷⁰OR ¹⁰⁷¹OR ¹⁰⁷²OR ¹⁰⁷³OR ¹⁰⁷⁴OR ¹⁰⁷⁵OR ¹⁰⁷⁶OR ¹⁰⁷⁷OR ¹⁰⁷⁸OR ¹⁰⁷⁹OR ¹⁰⁸⁰OR ¹⁰⁸¹OR ¹⁰⁸²OR ¹⁰⁸³OR ¹⁰⁸⁴OR ¹⁰⁸⁵OR ¹⁰⁸⁶OR ¹⁰⁸⁷OR ¹⁰⁸⁸OR ¹⁰⁸⁹OR ¹⁰⁹⁰OR ¹⁰⁹¹OR ¹⁰⁹²OR ¹⁰⁹³OR ¹⁰⁹⁴OR ¹⁰⁹⁵OR ¹⁰⁹⁶OR ¹⁰⁹⁷OR ¹⁰⁹⁸OR ¹⁰⁹⁹OR ¹¹⁰⁰OR ¹¹⁰¹OR ¹¹⁰²OR ¹¹⁰³OR ¹¹⁰⁴OR ¹¹⁰⁵OR ¹¹⁰⁶OR ¹¹⁰⁷OR ¹¹⁰⁸OR ¹¹⁰⁹OR ¹¹¹⁰OR ¹¹¹¹OR ¹¹¹²OR ¹¹¹³OR ¹¹¹⁴OR ¹¹¹⁵OR ¹¹¹⁶OR ¹¹¹⁷OR ¹¹¹⁸OR ¹¹¹⁹OR ¹¹²⁰OR ¹¹²¹OR ¹¹²²OR ¹¹²³OR ¹¹²⁴OR ¹¹²⁵OR ¹¹²⁶OR ¹¹²⁷OR ¹¹²⁸OR ¹¹²⁹OR ¹¹³⁰OR ¹¹³¹OR ¹¹³²OR ¹¹³³OR ¹¹³⁴OR ¹¹³⁵OR ¹¹³⁶OR ¹¹³⁷OR ¹¹³⁸OR ¹¹³⁹OR ¹¹⁴⁰OR ¹¹⁴¹OR ¹¹⁴²OR ¹¹⁴³OR ¹¹⁴⁴OR ¹¹⁴⁵OR ¹¹⁴⁶OR ¹¹⁴⁷OR ¹¹⁴⁸OR ¹¹⁴⁹OR ¹¹⁵⁰OR ¹¹⁵¹OR ¹¹⁵²OR ¹¹⁵³OR ¹¹⁵⁴OR ¹¹⁵⁵OR ¹¹⁵⁶

for a total daily dose of 3600mg/day.

ACETAMINOPHEN, OXYCODONE HCL (PERCOCET, ENDOCET, OXYCODONE/ACET, RIVACOCET)

Limited use benefit (prior approval is not required).

For safety reasons NIHB has implemented a dose limit on acetaminophen. The limit accumulates against the amount of acetaminophen claimed to the program from plain acetaminophen and/or acetaminophen in combination with opioids such as codeine (i.e. Tylenol® #3) or oxycodone (i.e. Percocet®). A total of 360 grams of acetaminophen is permitted in a 100-day period, for a total daily dose of 3600mg/day.

ASA, OXYCODONE HCL (OXYCODAN);

Limited use benefit (prior approval is not required).

To promote safe, therapeutically effective and efficient use of drug therapy NIHB has implemented an opioid dose limit of 400 mg morphine equivalents per day for non-cancer, non-palliative pain. This limit will be calculated based on the total dose of all opioids a client is receiving from NIHB within a 30-day period (i.e. 12000 morphine equivalents over 30 days).

CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE (CODEINE CONTIN CR)

Limited use benefit (prior approval required). For treatment of: a. - chronic pain and palliative care patients as an alternative to products containing codeine in combination with acetaminophen or ASA with or without caffeine, or b. - chronic pain and palliative care patients as an alternative to regular release codeine tablets when large doses are required.

To promote safe, therapeutically effective and efficient use of drug therapy NIHB has implemented an opioid dose limit of 400 mg morphine equivalents per day for non-cancer, non-palliative pain. This limit will be calculated based on the total dose of all opioids a client is receiving from NIHB within a 30-day period (i.e. 12000 morphine equivalents over 30 days).

CODEINE PHOSPHATE

Limited use benefit (prior approval is not required).

To promote safe, therapeutically effective and efficient use of drug therapy NIHB has implemented an opioid dose limit of 400 mg morphine equivalents per day for non-cancer, non-palliative pain. This limit will be calculated based on the total dose of all opioids a client is receiving from NIHB within a 30-day period (i.e. 12000 morphine equivalents over 30 days).

FENTANYL (FENTANYL, DURAGESIC)

Limited use benefit (prior approval required).

For the management of chronic pain in patients who are unresponsive or intolerant to at least one long-acting oral sustained released product, such as morphine, hydromorphone and oxycodone, despite appropriate dose titration and adjunctive therapy including laxatives and antiemetics.

To promote safe, therapeutically effective and efficient use of drug therapy NIHB has implemented an opioid dose limit of 400 mg morphine equivalents per day for non-cancer, non-palliative pain. This limit will be calculated based on the total dose of all opioids a client is receiving from NIHB within a 30-day period (i.e. 12000 morphine equivalents over 30 days).

HYDROMORPHONE HCL (HYDROMORPH, DILAUDID)

Limited use benefit. Prior approval required for controlled release capsules only. Regular release dosage forms are full benefits and do not require prior approval.

For treatment of moderate to severe chronic pain when other opioids such as morphine have been ineffective in controlling pain or in patients experiencing intolerable side effects.

To promote safe, therapeutically effective and efficient use of drug therapy NIHB has implemented an opioid dose limit of 400 mg morphine equivalents per day for non-cancer, non-palliative pain. This limit will be calculated based on the total dose of all opioids a client is receiving from NIHB within a 30-day period (i.e. 12000 morphine equivalents over 30 days).

METHADONE (METADOL)

Limited use benefit (prior approval required) with the following criteria:

Prescriber is registered with Health Canada and is eligible to prescribe methadone for the management of pain. AND For the management of moderate to severe cancer pain or chronic non-cancer pain, as an alternative to other opioids. OR For the management of pain for palliative care patients. Pharmacists may only dispense a maximum supply of 30 days at one time.

MORPHINE HCL (DOLORAL, MORPHINE)

Limited use benefit (prior approval is not required).

To promote safe, therapeutically effective and efficient use of drug therapy NIHB has implemented an opioid dose limit of 400 mg morphine equivalents per day for non-cancer, non-palliative pain. This limit will be calculated based on the total dose of all opioids a client is receiving from NIHB within a 30-day period (i.e. 12000 morphine equivalents over 30 days).

MORPHINE SULFATE (M-ESLON, STATEX, MORPHINE SR, MS CONTIN SR)

Limited use benefit (prior approval required).

To promote safe, therapeutically effective and efficient use of drug therapy NIHB has implemented an opioid dose limit of 400 mg morphine equivalents per day for non-cancer, non-palliative pain. This limit will be calculated based on the total dose of all opioids a client is receiving from NIHB within a 30-day period (i.e. 12000 morphine equivalents over 30 days).

MORPHINE SULFATE (KADIAN)

• For the treatment of opioid dependence where methadone and Suboxone are not available or not appropriate OR • For the treatment of chronic pain.

To promote safe, therapeutically effective and efficient use of drug therapy NIHB has implemented an opioid dose limit of 400 mg morphine equivalents per day for non-cancer, non-palliative pain. This limit will be calculated based on the total dose of all opioids a client is receiving from NIHB within a 30-day period (i.e. 12000 morphine equivalents over 30 days).

OXYCODONE HCL (SUPEUDOL)

Limited use benefit (prior approval is not required).

To promote safe, therapeutically effective and efficient use of drug therapy NIHB has implemented an opioid dose limit of 400 mg morphine equivalents per day for non-cancer, non-palliative pain. This limit will be calculated based on the total dose of all opioids a client is receiving from NIHB within a 30-day period (i.e. 12000 morphine equivalents over 30 days).

SUBOXONE (BUPRENORPHINE)

Limited use benefit (prior approval required). Limited use benefit (prior approval required).

For the treatment of opioid dependence when: • The client must be 16 years or older. • In cases where the client lives in a remote or isolated location, confirmation is required that the community has the ability to support Suboxone administration. These supports include the safe daily witnessing, storage and handling of the Suboxone doses. After this confirmation, NIHB will approve the Suboxone for the client.

ACETAMINOPHEN

Limited use benefit (prior approval is not required).

For safety reasons NIHB has implemented a dose limit on acetaminophen. The limit accumulates against the amount of acetaminophen claimed to the program from plain acetaminophen and/or acetaminophen in combination with opioids such as codeine (i.e. Tylenol® #3) or oxycodone (i.e. Percocet®). A total of 360 grams of acetaminophen is permitted in a 100-day period, for a total daily dose of 3600mg/day.

Limited Use Criteria – Neuropathic Pain Agents

GABAPENTIN

Limited use benefit (prior approval is not required).

For safety reasons NIHB has implemented a dose limit on gabapentin. The limit accumulates against the amount of gabapentin claimed to the program. A total of 400 grams of gabapentin is permitted in a 100-day period, for a total daily dose of 4000mg/day.

PREGABALIN

Limited use benefit (prior approval required). For the treatment of neuropathic pain in patients who have failed to effectively treat their pain with a tricyclic antidepressant (TCA)

OR For the treatment of neuropathic pain in patients who have a contraindication or intolerance with a TCA. The dose of pregabalin is limited to a maximum of 600 mg per day

Limited Use Criteria – Proton Pump Inhibitors (lansoprazole, omeprazole, pantoprazole, rabeprazole)

Prior approval not required.

The following PPI status change is primarily based on the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) report on optimal PPI therapy. The report concluded that:

- All PPIs are equally efficacious.
- Double dose PPI is not necessary for initial therapy
- Double dose PPI is effective in H. Pylori eradication; however, treatment is not needed beyond 14 days.

PPI use has been associated with increased risk of hip fracture, community-acquired pneumonia and Clostridium difficile associated diarrhea. Although further study is needed to establish clinical significance, it is prudent to use the lowest dose and shortest duration of therapy required to control symptoms.

All proton pump inhibitors (open benefit and limited use (LU) PPIs) have a maximum quantity limit of 400 tablets/capsules per 180 day period. This quantity limit will be in effect for the entire class of PPIs. For example, if a patient fills 30 tablets of rabeprazole, then switch to 30 tablets of omeprazole, then switch to 30 capsules of lansoprazole, this will count as 90 PP tablets/capsules towards the quantity limit.

•Patients taking two rabeprazole 10mg tablets a day can be switched to one rabeprazole 20mg tablet a day to avoid reaching the quantity limit. Patients taking two omeprazole 10mg tablets/capsules a day can be switched to one omeprazole 20mg tablet/capsule a day to avoid reaching the quantity limit

Patients with Zollinger Ellison Syndrome, Barrett's esophagus, erosive esophagitis and those who remain symptomatic on a single dose PPI will be eligible for additional doses above 400 tablets/capsules per 180 days through the prior approval process.

Previous Updates:

2016:

Methotrexate injections added to formulary! Here are the DINs:

Dose	DIN
7.5 mg	02422166
10 mg	02422174
15 mg	02422182
20 mg	02422190
25 mg	02422204